> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Chiesi Rare Diseases NDA Approved
- URL: https://www.fdaweb.com/chiesi-rare-diseases-nda-approved/
- Published: 2020-05-21T12:00:00.000Z
- Updated: 2026-09-14T16:15:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146832

FDA has approved a Chiesi Global Rare Diseases NDA for Ferriprox (deferiprone) twice-a-day tablets for treating patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. The company says the new formulation of twice-a-day Ferriprox 1,000 mg oral tablets eliminates a mid-day dose.

Thalassemia syndromes are rare inherited hematological conditions including beta-thalassemia and are characterized by impaired hemoglobin production, Chiesi says. In certain cases, such as with beta-thalassemia, severe forms of this genetic disorder can lead to life-threatening complications. Patients are often managed with long-term blood transfusions that can put them at risk of developing very high levels of iron in their blood and vital organs, it says.